PTC Therapeutics, Inc. Current Income Tax Expense (Benefit)
PTC Therapeutics, Inc. (PTCT) reported Current Income Tax Expense (Benefit) of -$485.00 thousand for the 12-month period ending 2015-12-31, per its 10-K filed 2016-02-29.
Discontinued › Expense Statement › Income Tax
us-gaap:CurrentIncomeTaxExpenseBenefit · last filed 2016-02-29
- PTC Therapeutics, Inc. current income tax expense (benefit) for fiscal 2015 was -$485.00K, a 110.33% decline from fiscal 2014.
- PTC Therapeutics, Inc. current income tax expense (benefit) for fiscal 2014 was $4.69M, a 234550.00% increase from fiscal 2013.
- PTC Therapeutics, Inc. current income tax expense (benefit) for fiscal 2013 was $2.00K.
| Period end | Current Income Tax Expense (Benefit) 12 month | Current Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2015-12-31 | -$485.00K 10-K · filed 2016-02-29 | |
| 2014-12-31 | $4.69M 10-K · filed 2016-02-29 | -$4.69M 10-K · filed 2015-03-02 |
| 2013-12-31 | $2.00K 10-K · filed 2015-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |